KR102297619B1 - 상처 치유 방법 - Google Patents

상처 치유 방법 Download PDF

Info

Publication number
KR102297619B1
KR102297619B1 KR1020207004865A KR20207004865A KR102297619B1 KR 102297619 B1 KR102297619 B1 KR 102297619B1 KR 1020207004865 A KR1020207004865 A KR 1020207004865A KR 20207004865 A KR20207004865 A KR 20207004865A KR 102297619 B1 KR102297619 B1 KR 102297619B1
Authority
KR
South Korea
Prior art keywords
wound
leu
ala
gly
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207004865A
Other languages
English (en)
Korean (ko)
Other versions
KR20200020994A (ko
Inventor
에블리나 바게스조
Original Assignee
일리야 팔마 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일리야 팔마 에이비 filed Critical 일리야 팔마 에이비
Publication of KR20200020994A publication Critical patent/KR20200020994A/ko
Application granted granted Critical
Publication of KR102297619B1 publication Critical patent/KR102297619B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207004865A 2014-12-23 2015-12-23 상처 치유 방법 Active KR102297619B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE1451658 2014-12-23
SE1451658-7 2014-12-23
KR1020177020505A KR102081493B1 (ko) 2014-12-23 2015-12-23 상처 치유 방법
PCT/EP2015/081146 WO2016102660A1 (en) 2014-12-23 2015-12-23 Methods for wound healing

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177020505A Division KR102081493B1 (ko) 2014-12-23 2015-12-23 상처 치유 방법

Publications (2)

Publication Number Publication Date
KR20200020994A KR20200020994A (ko) 2020-02-26
KR102297619B1 true KR102297619B1 (ko) 2021-09-02

Family

ID=55080095

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207004865A Active KR102297619B1 (ko) 2014-12-23 2015-12-23 상처 치유 방법
KR1020177020505A Active KR102081493B1 (ko) 2014-12-23 2015-12-23 상처 치유 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177020505A Active KR102081493B1 (ko) 2014-12-23 2015-12-23 상처 치유 방법

Country Status (9)

Country Link
US (3) US10696974B2 (https=)
EP (2) EP3237622B1 (https=)
JP (2) JP6581208B2 (https=)
KR (2) KR102297619B1 (https=)
CN (2) CN113403244B (https=)
AU (2) AU2015370982B2 (https=)
CA (1) CA2971520C (https=)
ES (2) ES2864373T3 (https=)
WO (1) WO2016102660A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102752056B1 (ko) * 2023-07-12 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리(Lactobacillus reuteri) NCHBL-005 균주를 포함하는 창상 예방 또는 치료, 피부 재생 촉진용 조성물

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973852B2 (en) 2016-01-25 2021-04-13 Nantcell, Inc. NK cells with altered CXCL12/CXCR4 signaling
US20190300843A1 (en) * 2016-10-31 2019-10-03 Kimberly-Clark Worldwide, Inc. Method for archiving a microbiome
US20240024388A1 (en) * 2017-02-17 2024-01-25 The University Of British Columbia Probiotic compositions and uses thereof
CN110157733A (zh) * 2018-02-11 2019-08-23 四川大学 重组mIL-22BP载体、脂质体复合物及其制备方法和用途
CN112236513B (zh) 2018-07-24 2023-09-19 生命大地女神有限公司 选择和使用褪黑素支持细菌以减少婴儿绞痛
CA3103356A1 (en) * 2018-07-24 2020-01-30 Biogaia Ab Therapeutic methods using bacterial strains which are capable of increasing adenosine levels
CN109112155A (zh) * 2018-08-02 2019-01-01 南昌大学 乳酸乳球菌mg1363的构建及其在治疗细菌性阴道炎中的应用
CN109234298A (zh) * 2018-10-30 2019-01-18 南昌大学 一种卷曲乳杆菌atcc55221的构建及其在治疗产妇乳头皲裂中的应用
CN109517772A (zh) * 2018-10-30 2019-03-26 南昌大学 一种乳酸乳球菌mg1363的构建及其在治疗产妇乳头皲裂中的应用
JP7045671B2 (ja) * 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
WO2020261055A1 (en) * 2019-06-24 2020-12-30 Mendes S.R.L. Composition with antibacterial and re-epithelializing action including probiotics
CN110623792B (zh) * 2019-09-23 2022-05-06 温州医科大学附属第一医院 一种医学敷料及其制备方法
CN114470007B (zh) * 2020-11-13 2024-10-18 葡萄王生技股份有限公司 含乳酸菌发酵产物之皮肤创伤外用组合物及其用途
CA3228922A1 (en) 2021-10-11 2023-04-20 Ajinomoto Co., Inc. Bacterium modified to express heterologous tat protein
WO2023118327A1 (en) 2021-12-22 2023-06-29 Ilya Pharma Ab Live bacteria as excipients for proteins
JP2025504333A (ja) * 2021-12-29 2025-02-12 イリヤ ファーマ エービー 治療誘発腸症の処置
GB202405882D0 (en) 2024-04-26 2024-06-12 Ilya Pharma Ab Treatment of mdr infections
CN118948906B (zh) * 2024-10-16 2025-02-14 温州医科大学附属第一医院 一种促进创面愈合的乳酸杆菌生物膜衍生物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014806A2 (en) 1995-10-20 1997-04-24 Cambridge University Technical Services Limited Delivery of biologically active polypeptides

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE438718T1 (de) * 1997-02-07 2009-08-15 Shionogi & Co Neuer cxc chemokinrezeptor aus maus
PT1739178E (pt) 1999-07-05 2010-11-17 Actogenix Nv Libertação de péptidos trifólios
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
WO2006124013A2 (en) * 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
US9200249B2 (en) 2004-08-20 2015-12-01 Actogenix N.V. Method to improve Lactococcus preservation
ES2626610T3 (es) 2005-08-30 2017-07-25 Intrexon Actobiotics Nv Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal
WO2007039586A1 (en) 2005-10-03 2007-04-12 Actogenix Nv Use of recombinant yeast strain producing an anti -inflammatory compound in the manufacture of a medicament to treat colitis
ES2405552T3 (es) 2005-11-29 2013-05-31 Actogenix N.V. Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
US8852916B2 (en) 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
EP2016178B1 (en) 2006-05-02 2017-07-12 Intrexon Actobiotics NV Microbial intestinal delivery of obesity related peptides
CA2672229A1 (en) 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
CA2673409A1 (en) 2006-12-19 2009-06-26 Ferrosan A/S Wound or tissue dressing comprising lactic acid bacteria
US20100143447A1 (en) 2006-12-19 2010-06-10 Ferrosan A/S Wound or tissue dressing comprising lactic acid bacteria
AU2008204442B2 (en) 2007-01-12 2013-03-14 Intrexon Actobiotics Nv Lactococcus promoters and uses thereof
WO2008090223A2 (en) 2007-01-25 2008-07-31 Actogenix N.V. Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
WO2008096359A2 (en) * 2007-02-08 2008-08-14 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
WO2008155120A2 (en) 2007-06-20 2008-12-24 Actogenix Nv Methods and compositions for treating mucositis
EP2218459B1 (en) 2007-11-07 2012-02-01 Ono Pharmaceutical Co., Ltd. Sustained release composition containing sdf-1
CA2709398C (en) 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
US8367109B2 (en) 2008-04-09 2013-02-05 Brookhaven Science Associates, Llc Microbes encapsulated within crosslinkable polymers
EP3181682B1 (en) 2008-09-29 2021-04-21 Intrexon Actobiotics NV Reduced colonization of microbes at the mucosa
US20100143305A1 (en) * 2008-12-08 2010-06-10 James Allen Lemke Treatment of hiv and aids using probiotic lactobacillus reuteri
US20120058086A1 (en) 2009-04-21 2012-03-08 Velazquez Omaida C Compositions, kits, and methods for promoting ischemic and diabetic wound healing
EP2243487A1 (en) 2009-04-23 2010-10-27 Actogenix N.V. Enteric coated formulation
CA2760248C (en) 2009-04-30 2019-05-28 Actogenix Nv Cryoprotectants for freeze drying of lactic acid bacteria
CN102459571B (zh) * 2009-06-04 2014-01-08 香港中文大学 抗炎细菌
CL2009001506A1 (es) 2009-07-01 2009-09-25 Univ Concepcion Parche o aposito a base de hidrocoloides compuesto por una lamina de gelatina reticulada que comprende cepas viables probioticas productoras de acido lactico de lactobacillus acidophilus dsm 17371, un agente reticulante y un agente plastificante; y proceso para elaborar dicho parche.
WO2011026041A2 (en) 2009-08-28 2011-03-03 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
US20120183503A1 (en) 2009-09-29 2012-07-19 Actogenix N.V. Lactobacillus and streptococcus promoters and uses thereof
GB2482536B (en) * 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
CN101985052B (zh) 2010-08-31 2013-11-06 中国人民解放军第二军医大学 自动捕获内皮祖细胞促进血管化的皮肤替代物及其构建方法
US20140065209A1 (en) 2011-05-03 2014-03-06 Dupont Nutrition Biosciences Aps Probiotic bacteria for the topical treatment of skin disorders
WO2012164083A1 (en) 2011-06-01 2012-12-06 Actogenix N.V. Polycistronic expression system for bacteria
JP6117212B2 (ja) 2011-09-23 2017-04-19 イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ 改変されたグラム陽性菌及びその使用
HUE038336T2 (hu) 2011-09-23 2018-10-29 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
EA031883B1 (ru) 2013-03-15 2019-03-29 Джувентас Терапьютикс, Инк. Способ ингибирования и/или снижения образования рубцовой ткани
WO2014146202A1 (en) * 2013-03-18 2014-09-25 London Health Sciences Centre Research Inc. Bacteria for the prevention, treatment and diagnosis of breast cancer
CN105658217B (zh) 2013-04-29 2021-03-19 约翰霍普金斯大学 经由自体干细胞动员的创伤愈合
WO2016124239A1 (en) 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014806A2 (en) 1995-10-20 1997-04-24 Cambridge University Technical Services Limited Delivery of biologically active polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Medical Hypotheses. Vol. 73, No. 5, 페이지 860 (2009.11.)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102752056B1 (ko) * 2023-07-12 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리(Lactobacillus reuteri) NCHBL-005 균주를 포함하는 창상 예방 또는 치료, 피부 재생 촉진용 조성물

Also Published As

Publication number Publication date
US10696974B2 (en) 2020-06-30
JP2020005646A (ja) 2020-01-16
KR102081493B1 (ko) 2020-02-26
KR20200020994A (ko) 2020-02-26
EP3237622A1 (en) 2017-11-01
EP3735979A1 (en) 2020-11-11
JP2018502600A (ja) 2018-02-01
US11473091B2 (en) 2022-10-18
CA2971520C (en) 2024-04-09
CN107208107A (zh) 2017-09-26
CA2971520A1 (en) 2016-06-30
EP3735979C0 (en) 2025-08-13
JP7033109B2 (ja) 2022-03-09
CN113403244B (zh) 2022-08-19
AU2015370982B2 (en) 2019-03-21
JP6581208B2 (ja) 2019-09-25
CN113403244A (zh) 2021-09-17
CN107208107B (zh) 2021-07-09
EP3237622B1 (en) 2021-02-24
US20180187202A1 (en) 2018-07-05
CN107208107A8 (zh) 2017-12-26
ES2864373T3 (es) 2021-10-13
KR20170097194A (ko) 2017-08-25
EP3735979B1 (en) 2025-08-13
ES3048233T3 (en) 2025-12-09
AU2019204290A1 (en) 2019-07-04
AU2015370982A1 (en) 2017-07-13
US20200299703A1 (en) 2020-09-24
WO2016102660A1 (en) 2016-06-30
AU2019204290B2 (en) 2021-12-16
US20230093013A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
AU2019204290B2 (en) Methods for wound healing
CN107438666B (zh) 重组益生菌
KR20160005333A (ko) 흉터 형성을 완화시키기 위한 sdf-1의 용도
AU719526B2 (en) New form of amphiregulin, methods for producing and using the same and compositions comprising the same
HK40061829B (en) Methods for wound healing
HK40061829A (en) Methods for wound healing
HUE032520T2 (en) A pharmaceutical composition containing PCMV-VEGF165 to stimulate angiogenesis
US20240285701A1 (en) Compositions and methods for treating skin conditions
Yong et al. Stability analysis of recombinant human TFF2 and its therapeutic effect on burn-induced gastric injury in mice
US20170266354A1 (en) Cell-Based Device For Local Treatment With Therapeutic Protein
HK1242736B (en) Methods for wound healing

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5